Insulet Corporation PODD Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$146.51 down $9.61, 6.16% at close Nov 6
Last close · Previous close $156.12
- Market cap
- $10.16BAt the Nov 6 close
- P/E ratio
- 23.90On last 12 months’ EPS
- Diluted EPS
- $6.13Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$146.51down $9.61, 6.16%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$156.12Nov 5
- Volume1.57MNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume1.45MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $126.40 to $354.88; now $146.51
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
PODD beat the S&P 500 in 3 of 7 periods.
| Period | PODD and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | PODD: up 8.7% S&P 500: down 5.6% | PODD beat the S&P 500 by 14.3 percentage points Beat |
| 3M | PODD: up 5.2% S&P 500: down 4.1% | PODD beat the S&P 500 by 9.3 percentage points Beat |
| YTD | PODD: down 48.5% S&P 500: up 8.7% | PODD trailed the S&P 500 by 57.2 percentage points Trailed |
| 1Y | PODD: down 54.7% S&P 500: up 10.9% | PODD trailed the S&P 500 by 65.6 percentage points Trailed |
| Long term | ||
| 3Y | PODD: down 7.8% S&P 500: up 75.0% −2.7% vs +20.5% a year | PODD trailed the S&P 500 by 82.8 percentage points Trailed |
| 5Y | PODD: down 52.4% S&P 500: up 67.8% −13.8% vs +10.9% a year | PODD trailed the S&P 500 by 120.2 percentage points Trailed |
| 10Y | PODD: up 315.9% S&P 500: up 313.1% +15.3% vs +15.2% a year | PODD beat the S&P 500 by 2.8 percentage points Beat |
$10,000 invested in PODD 10 years ago (Nov 4, 2016) would be worth about $41,587 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
PODD beat the S&P 500 in 3 of 7 periods.
| Period | PODD and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | PODD: up 8.7% S&P 500: down 5.6% | PODD beat the S&P 500 by 14.3 percentage points Beat |
| 3M | PODD: up 5.2% S&P 500: down 4.3% | PODD beat the S&P 500 by 9.5 percentage points Beat |
| YTD | PODD: down 48.5% S&P 500: up 7.8% | PODD trailed the S&P 500 by 56.3 percentage points Trailed |
| 1Y | PODD: down 54.7% S&P 500: up 9.7% | PODD trailed the S&P 500 by 64.4 percentage points Trailed |
| Long term | ||
| 3Y | PODD: down 7.8% S&P 500: up 68.8% −2.7% vs +19.1% a year | PODD trailed the S&P 500 by 76.6 percentage points Trailed |
| 5Y | PODD: down 52.4% S&P 500: up 56.9% −13.8% vs +9.4% a year | PODD trailed the S&P 500 by 109.3 percentage points Trailed |
| 10Y | PODD: up 315.9% S&P 500: up 252.6% +15.3% vs +13.4% a year | PODD beat the S&P 500 by 63.3 percentage points Beat |
$10,000 invested in PODD 10 years ago (Nov 4, 2016) would be worth about $41,587 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$352.82
Closing high on . Now 58.5% below that record.
Split-adjusted daily closes since May 15, 2007.
Stock splits
PODD hasn’t split since its price history begins in 2007.
Valuation
The Nov 6 close compared with the last 12 months of reported results (the four quarters to Sep 30, 2026). Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
23.9×The Nov 6 close ÷ diluted EPS over the last 12 months ($6.13)
The range covers daily P/E ratios from Oct 29, 2021 to Nov 6, 2026, each based on the previous 12 months of earnings.
PODD trades at 23.9× its earnings over the last 12 months, below its 5-year median of 64.8×. In plain terms, buyers are paying about $24 for each $1 of profit from the past year. How to read P/E
Other valuation measures
- 3.2×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - 6.4×Book value as of Sep 30, 2026
Price relative to accounting equity (book value) per share on the Sep 30, 2026 balance sheet. Asset-light companies often trade far above book value.
P/B = Price ÷ Book value per sharePrice-to-book ratio - 14.8×Last 12 months’ EBITDA
Enterprise value divided by EBITDA over the last 12 months. It compares companies with different amounts of debt.
EV/EBITDA = Enterprise value ÷ EBITDA (last 12 months)EV/EBITDA explained - 0.31Last 12 months’ EPS growth
The P/E divided by the growth in diluted EPS over the last 12 months (+78.2% on the 12 months before). It looks backward: near 1 means the P/E roughly matches last year’s growth. Sites that use analysts’ growth forecasts show a different PEG.
PEG = P/E ÷ EPS growth (%) = 23.9 ÷ 78.2 - 2.29%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $10.54BAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Sep 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own PODD DCF in Excel. Value Insulet with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q3 FY26, the quarter ended Sep 30, 2026. “Last 12 months” means the four quarters from Oct 1, 2025 to Sep 30, 2026, and balance-sheet figures are as of Sep 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $3.19Bup 26.5%
- Net income
- $428.80Mup 74.2%
- Diluted EPS
- $6.13up 78.2%
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q4 FY24 (Dec 31, 2024) | $597.50M | $100.70M | $1.38 |
| Q1 FY25 (Mar 31, 2025) | $569.00M | $35.40M | $0.50 |
| Q2 FY25 (Jun 30, 2025) | $649.10M | $22.50M | $0.32 |
| Q3 FY25 (Sep 30, 2025) | $706.30M | $87.60M | $1.24 |
| Q4 FY25 (Dec 31, 2025) | $783.80M | $101.60M | $1.43 |
| Q1 FY26 (Mar 31, 2026) | $761.70M | $91.10M | $1.30 |
| Q2 FY26 (Jun 30, 2026) | $801.70M | $95.00M | $1.37 |
| Q3 FY26 (Sep 30, 2026) | $842.00M | $141.10M | $2.03 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $1.10B | $16.80M | $0.24 |
| FY22 (Dec 31, 2022) | $1.31B | $4.60M | $0.07 |
| FY23 (Dec 31, 2023) | $1.70B | $206.30M | $2.94 |
| FY24 (Dec 31, 2024) | $2.07B | $418.30M | $5.78 |
| FY25 (Dec 31, 2025) | $2.71B | $247.10M | $3.48 |
Margins
- Gross 71.9%
- Operating 18.4%
- Net 13.4%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- $232.60MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow$509.00MLast 12 months
- Capital spending$276.40MLast 12 months
- 7.3%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $280.80MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$280.80MLast 12 months
121% of free cash flow
Balance sheet
- $584.40MAs of Sep 30, 2026
Cash plus short- and long-term marketable securities on the Sep 30, 2026 balance sheet.
- Total debt$962.10MAs of Sep 30, 2026
- Net debt$377.70MAs of Sep 30, 2026
- 2.51As of Sep 30, 2026
Current assets divided by current liabilities on the Sep 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.61As of Sep 30, 2026
Total debt divided by shareholders’ equity on the Sep 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 8 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✓Net income was positive: passed
- ✓Operating cash flow was positive: passed
- ✓Return on assets improved: passed
- ✓Operating cash flow exceeded net income: passed
- ✓Long-term debt fell relative to assets: passed
- ✗Current ratio improved: not passed
- ✓Share count didn’t rise: passed
- ✓Gross margin improved: passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- 29.5%Last 12 months
Over the last 12 months, Insulet’s net income was 29.5% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - 13.4%Last 12 months
Over the last 12 months, Insulet’s net income was 13.4% of its total assets (averaged over the last four quarter-ends): what the business earned on everything it owns.
ROA = Net income (last 12 months) ÷ Average total assets
About Insulet Corporation
Insulet Corporation, headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas.
- Sector
- Healthcare
- Industry
- Medical Devices
- Headquarters
- Massachusetts, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
PODD news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
PODD stock FAQ
What is PODD stock’s price today?
Insulet (PODD) traded at $146.51 at the close on , down $9.61 (6.16%) from the previous close of $156.12. Over the past 52 weeks it has traded between $126.40 and $354.88.
If you invested $1,000 in PODD 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in PODD on would be worth about $4,159 at the close on , a total return of +315.9%. The same $1,000 would be worth $476 if invested five years ago and $453 if invested one year ago. Past performance doesn’t predict future returns.
What is Insulet’s market cap?
Insulet’s market capitalization is about $10.2 billion. That’s Tiingo’s daily market cap for , at that day’s closing price of $146.51 (how market cap works). Insulet reported 69.35M shares outstanding at the end of its latest quarter ().
What is PODD’s P/E ratio?
PODD trades at 23.9 times its diluted earnings over the four quarters to ($6.13 per share), at the close. Over the past five years its P/E has ranged from 21.1 to 999.6, with a median of 64.8. (How the P/E ratio works.)
How much revenue does Insulet make?
Insulet reported $3.2 billion of revenue over the four quarters to , up 26.5% from the twelve months before. In its latest quarter (Q3 FY26, ended ) revenue was $842.0 million, up 19.2% from a year earlier.
Is Insulet profitable?
Yes. Insulet earned $428.8 million of net income over the four quarters to , a net margin of 13.4%, and its operating margin was 18.4% (what margins tell you).
What are PODD’s earnings per share?
PODD’s diluted earnings per share were $6.13 over the four quarters to , compared with $3.44 in the twelve months before. The latest quarter (Q3 FY26) brought $2.03 per share, against $1.24 a year earlier (how EPS works).
Does PODD pay a dividend?
Insulet hasn’t paid a dividend in the last twelve months.
What is PODD’s 52-week high and low?
Over the past 52 weeks PODD has traded as low as $126.40 and as high as $354.88. At $146.51 at the close on , it is 58.7% below that high and 15.9% above the low.
What is PODD’s all-time high?
PODD’s highest closing price was $352.82 on , adjusted for stock splits. At $146.51 at the close on , it is 58.5% below that record.
Has PODD stock ever split?
No. PODD hasn’t split since its price history begins in 2007.
How has PODD stock performed?
Including dividends and measured to the close on , PODD has returned −48.5% so far this year and −54.7% over the past year, and −52.4% over five years (−13.8% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Insulet in?
Insulet is in the Healthcare sector and the Medical Devices industry, and is headquartered in Massachusetts, USA.
What exchange does PODD trade on?
Insulet trades on the Nasdaq under the ticker symbol PODD. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.